NCT04680637终止2 期
A Phase 2b Dose Ranging Study to Evaluate the Efficacy and Safety of Efavaleukin Alfa in Subjects With Active Systemic Lupus Erythematosus With Inadequate Response to Standard of Care Therapy
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 发起方
- Amgen
- 入组人数
- 168
- 试验地点
- 149
- 主要终点
- Number of Participants Who Achieved a Systemic Lupus Erythematosus Responder Index 4 (SRI-4) Response at Week 52
研究概览
简要总结
The primary objective is to evaluate the efficacy and safety of efavaleukin alfa in subjects with active systemic lupus erythematosus.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participant has provided informed consent prior to initiation of any study specific activities/procedures.
- •Participant is aged between 18 and
- •Fulfills classification criteria for systemic lupus erythematosus (SLE) according to the 2019 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) classification criteria for SLE with antinuclear antibody ≥ 1:80 by immunofluorescence on Hep-2 cells being present at screening.
- •Hybrid SLEDAI score ≥ 6 points with a "Clinical" hSLEDAI score ≥ 4 points. The "Clinical" hSLEDAI is the hSLEDAI assessment score without the inclusion of points attributable to laboratory results, including urine or immunologic parameters.
- •British-Isles Lupus Assessment Group (BILAG) index score (BILAG 2004) of ≥ 1 A item or ≥ 2 B items.
- •Must be taking ≥ 1 of the following SLE treatments (or regional equivalent): hydroxychloroquine, chloroquine, quinacrine, mycophenolate mofetil, azathioprine, methotrexate, dapsone, or oral calcineurin inhibitors, or OCS. A participant may enter the study on OCS alone (prednisone ≥ 10 mg/day or equivalent) only if the participant has previously documented trial of anti-malarial or immunosuppressant treatment for SLE. Participants must be on a stable dose for ≥ 8 weeks prior to screening for all antimalarials and immunosuppressants, with the exception of OCS doses which must be stable for ≥ 2 weeks prior to screening.
- •For participants taking OCS, dose must be ≤ 20 mg/day of prednisone or OCS equivalent, and the dose must be stable at baseline visit and for ≥ 2 weeks prior to screening visit.
- •Stability of SLE treatments: OCS and other immunosuppressants/immunomodulator agents and doses must be stable since screening visit.
- •Disease activity: active disease as indicated by clinical hSLEDAI score ≥ 4 must be observed (clinical hSLEDAI score is the hSLEDAI assessment score without the inclusion of points attributable to laboratory results including urine and immunologic parameters).
排除标准
- •Lupus nephritis if any of the following are present: urine protein creatinine ratio ≥ 2000 mg/g (or equivalent) at screening, OR requiring induction therapy currently or within 1 year prior to screening, OR histological evidence (if available) of diffuse proliferative glomerulonephritis within 12 weeks prior to screening.
- •Active CNS lupus within 1 year prior to screening including, but not limited to, aseptic meningitis, ataxia, CNS vasculitis, cranial neuropathy, demyelinating syndrome, optic neuritis, psychosis, seizures, or transverse myelitis.
- •Currently present or within 1 year prior to screening a diagnosis of any chronic inflammatory disease other than SLE (eg, rheumatoid arthritis) which would interfere with SLE disease assessment.
- •History of any disease other than SLE that has required treatment with oral or parenteral corticosteroids for > 2 weeks within 4 months prior to screening.
- •Active infection (including chronic or localized infections) for which anti-infectives are indicated currently or within 4 weeks prior to screening visit OR presence of serious infection, defined as requiring hospitalization or intravenous anti-infectives within 8 weeks prior to screening visit.
- •Active tuberculosis or latent tuberculosis with no documented past history of adequate treatment per local standard of care.
- •Positive test for tuberculosis during creening defined as: either a positive or indeterminate QuantiFERON®-TB or T-spot test OR positive purified protein derivative (PPD) (≥5 mm of induration at 48 to 72 hours after test is placed).
- •Positive for hepatitis B surface antigen (HBsAg); or positive for hepatitis B core antibody (HBcAb). A history of hepatitis B vaccination without history of hepatitis B infection (ie, positive hepatitis B surface antibody (HBsAb), negative HBsAg and negative HBcAb) is allowed.
- •Positive for hepatitis C antibody.
- •Known history of HIV or positive HIV test at screening.
- •Presence of 1 or more significant concurrent medical conditions, including but not limited to the following:
- •poorly controlled diabetes (hemoglobin A1C > 7) or hypertension
- •symptomatic heart failure (New York Heart Association class III or IV)
- •myocardial infarction or unstable angina pectoris within the past 12 months prior to screening
- •severe chronic pulmonary disease requiring oxygen therapy
- •multiple sclerosis or any other demyelinating disease
- •Any history of malignancy with the following exceptions:
- •resolved non-melanoma skin cancers > 5 years prior to screening
- •resolved cervical carcinoma > 5 years prior to screening
- •resolved breast ductal carcinoma in situ > 5 years of screening
- •Currently receiving or had treatment with: cyclophosphamide, chlorambucil, nitrogen mustard, or any other alkylating agent within 6 months prior to screening or sirolimus within 4 weeks prior screening.
- •Currently receiving or had treatment with a Janus kinase (JAK) inhibitor within 3 months or less than 5 drug half-lives (whichever is longer) prior to screening.
- •Currently receiving or had treatment with an immune checkpoint inhibitor (eg, programmed death 1 [PD-1] inhibitor, programmed death ligand 1 [PD-L1] inhibitor, cytotoxic T-lymphocyte associated protein 4 [CTLA-4] inhibitor).
- •Note: Abatacept is not considered a CTLA-4 inhibitor and is referred to below.
- •Currently receiving or had treatment within 12 months prior to screening with T-cell depleting agents (eg, antithymocyte globulin, Campath).
- •Currently receiving of had treatment with an interleukin 2 (IL-2) based therapy (eg, Proleukin).
- •Current or previous treatment with a biologic agent with immunosuppressive/immunomodulatory activity as follows: rituximab within 6 months prior to screening; abatacept and belimumab within the past 3 months prior to screening; other biologics within < 5 drug half lives prior to screening.
- •Participants who have received intraarticular, intralesional, or intramuscular corticosteroids within 2 weeks prior to screening or intravenous corticosteroids within 6 weeks prior to screening.
- •Participants who have received live vaccines within 5 weeks prior to screening, or plan to receive live vaccines during the treatment period and up to 6 weeks after the end of treatment period in the study.
- •Currently receiving treatment in another investigational device or drug study.
- •Ending a treatment with an investigational drug or investigational device less than 3 months or 5 half-lives from the last dose of the investigational drug (whichever is longer) at screening.
研究组 & 干预措施
Placebo + Standard of Care
Placebo Comparator
干预措施: Placebo (Drug)
Placebo + Standard of Care
Placebo Comparator
干预措施: Standard of Care (Other)
Efavaleukin Alfa Dose Level One + Standard of Care
Experimental
干预措施: Efavaleukin Alfa (Drug)
Efavaleukin Alfa Dose Level One + Standard of Care
Experimental
干预措施: Standard of Care (Other)
Efavaleukin Alfa Dose Level Two + Standard of Care
Experimental
干预措施: Efavaleukin Alfa (Drug)
Efavaleukin Alfa Dose Level Two + Standard of Care
Experimental
干预措施: Standard of Care (Other)
Efavaleukin Alfa Dose Level Three + Standard of Care
Experimental
干预措施: Efavaleukin Alfa (Drug)
Efavaleukin Alfa Dose Level Three + Standard of Care
Experimental
干预措施: Standard of Care (Other)
结局指标
主要结局
Number of Participants Who Achieved a Systemic Lupus Erythematosus Responder Index 4 (SRI-4) Response at Week 52
时间窗: Week 52
A participant achieved an SRI-4 response if all the following criteria were met: * ≥ 4-point reduction from baseline in Hybrid Systemic Lupus Erythematosus Disease Activity Index (hSLEDAI) score (scale 0-105, with higher scores indicating more disease activity). * No new British-Isles Lupus Assessment Group (BILAG) A score and no \> 1 new BILAG B organ domain scores compared with baseline. The BILAG index evaluates disease activity in 9 separate organ systems. Each of the organ systems are allocated an alphabetical score of A (most active), B (moderate activity), C (minor activity), D (stable) or E (never present). * \< 0.3-points deterioration from baseline in Physician Global Assessment (PGA) visual analogue (VAS) score (scale 0 to 3, with higher scores indicating more severe disease). Participants were considered non-responders for using more than protocol-permitted therapies.
次要结局
- Number of Participants Who Achieved a Lupus Low Disease Activity State (LLDAS) Response at Week 52(Week 52)
- Number of Participants Who Achieved a BILAG-based Composite Lupus Assessment (BICLA) Response at Week 52(Week 52)
- Number of Participants With a Reduction of Oral Corticosteroids (OCS) to ≤ 7.5 mg/Day by Week 44 and Sustained Through Week 52 in Participants With a Baseline OCS Dose ≥ 10 mg/Day(Baseline to Week 52)
- Number of Participants With an Improvement From Baseline in Cutaneous Lupus Erythematosus Area and Severity Index (CLASI) Activity Score ≥ 50% at Week 8, 12, 24, 36, and 52 in Participants With a CLASI Activity Score ≥ 8 at Baseline(Weeks 8, 12, 24, 36 and 52)
- Change From Baseline in Fatigue Standardized Score Using the Patient-Reported Outcome Measurement Information System (PROMIS) Fatigue Short Form (SF) 7a Instrument at Week 12, 24, 36 and 52(Baseline to Week 12, 24, 36 and 52)
- Number of Participants With a hSLEDAI Response at Week 24 and Week 52(Week 24 and Week 52)
- Annualized Flare Rate Over 52 Weeks(Up to 52 weeks)
- Number of Participants Who Achieved a SRI-4 Response at Week 24(Week 24)
- Change From Baseline in the Physical Role Functioning Domain Score of the SF-36V2 at Week 12, 24, 36 and 52(Baseline to Week 12, 24, 36 and 52)
- Change From Baseline in the Mental Health Domain Score of the SF-36V2 at Week 12, 24, 36 and 52(Baseline to Week 12, 24, 36 and 52)
- Change From Baseline in the Planning Domain Score of the LupusQoL at Week 12, 24, 36 and 52(Baseline to Week 12, 24, 36 and 52)
- Change From Baseline in the Fatigue Domain Score of the LupusQoL at Week 12, 24, 36 and 52(Baseline to Week 12, 24, 36 and 52)
- Number of Participants Who Achieved a BICLA Response at Week 24(Week 24)
- Number of Participants With an Improvement From Baseline in Tender and Swollen Joint Count ≥ 50% at Weeks 8, 12, 24, 36, and 52 in Participants With ≥ 6 Tender and Swollen Joints in Hands and Wrists(Weeks 8, 12, 24, 36 and 52)
- Change From Baseline in the Emotional Role Domain Score of the SF-36V2 at Week 12, 24, 36 and 52(Baseline to Week 12, 24, 36 and 52)
- Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE)(Day 1 to Week 56)
- Serum Efavaleukin Alfa Concentrations by Timepoint(Day 1: 6-24 and 48-96 hrs, Day 29, Day 43: 6-24 and 48-96 hrs, Day 85, Day 169, Day 253, Day 309, and Day 365)
- Change From Baseline in the Physical Component Score of the Medical Outcomes Short Form-36 Questionnaire Version 2 (SF-36V2) at Week 12, 24, 36 and 52(Baseline to Week 12, 24, 36 and 52)
- Change From Baseline in the Mental Component Score of the SF-36V2 at Week 12, 24, 36 and 52(Baseline to Week 12, 24, 36 and 52)
- Change From Baseline in the Physical Functioning Domain Score of the SF-36V2 at Week 12, 24, 36 and 52(Baseline to Week 12, 24, 36 and 52)
- Change From Baseline in the Bodily Pain Domain Score of the SF-36V2 at Week 12, 24, 36 and 52(Baseline to Week 12, 24, 36 and 52)
- Change From Baseline in the Vitality Domain Score of the SF-36V2 at Week 12, 24, 36 and 52(Baseline to Week 12, 24, 36 and 52)
- Change From Baseline in the Physical Health Domain Score of the Lupus Quality of Life (LupusQoL) at Week 12, 24, 36 and 52(Baseline to Week 12, 24, 36 and 52)
- Change From Baseline in the Social Role Functioning Domain Score of the SF-36V2 at Week 12, 24, 36 and 52(Baseline to Week 12, 24, 36 and 52)
- Change From Baseline in the Intimate Relationship Domain Score of the LupusQoL at Week 12, 24, 36 and 52(Baseline to Week 12, 24, 36 and 52)
- Change From Baseline in the Emotional Health Domain Score of the LupusQoL at Week 12, 24, 36 and 52(Baseline to Week 12, 24, 36 and 52)
- Change From Baseline in the General Health Domain Score of the SF-36V2 at Week 12, 24, 36 and 52(Baseline to Week 12, 24, 36 and 52)
- Change From Baseline in the Pain Domain Score of the LupusQoL at Week 12, 24, 36 and 52(Baseline to Week 12, 24, 36 and 52)
- Change From Baseline in the Burden to Others Domain Score of the LupusQoL at Week 12, 24, 36 and 52(Baseline to Week 12, 24, 36 and 52)
- Change From Baseline in the Body Image Domain Score of the LupusQoL at Week 12, 24, 36 and 52(Baseline to Week 12, 24, 36 and 52)
研究者
研究点 (149)
Loading locations...
相似试验
终止
2 期
Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative ColitisUlcerative ColitisNCT04987307Amgen221
已完成
1 期
Study of Efavaleukin Alfa in Healthy Chinese, Japanese, and Caucasian ParticipantsInflammatory DiseasesNCT04987333Amgen32
已完成
1 期
A Study to Evaluate Once-Daily Oral VT-464 in Patients With Castration-Resistant Prostate CancerCastration-resistant Prostate CancerCRPCNCT02361086Innocrin Pharmaceutical21
终止
1 期
Safety and Efficacy of Efavaleukin Alfa in Subjects With Steroid Refractory Chronic Graft Versus Host DiseaseChronic Graft Versus Host Disease cGVHDNCT03422627Amgen32
已完成
2 期
Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE)Systemic Lupus Erythematosus (SLE)NCT04058028Amgen244